CABG Cabg Medical (MM)

CABG Medical Announces Approval to Expand Clinical Trials Into Europe MINNEAPOLIS, June 3 /PRNewswire-FirstCall/ -- CABG Medical, Inc. (NASDAQ:CABG) today announced it has received approval from regulatory authorities to evaluate the Holly Graft System in clinical trials at various centers in Germany. The Holly Graft(TM) System, is a drug eluting graft (DEG) for facilitating a coronary artery bypass procedure. (Logo: http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO ) "The approval to begin clinical trials in Germany allows us to begin the evaluation of our technology in what we believe will be the third largest worldwide market for the Holly Graft System," said Manny Villafana, Chairman and CEO. "The approval to begin clinical trials represents a tremendous opportunity for CABG Medical to begin working with some of the largest hospitals in the world and on expanded base of qualified physicians." The clinical trial is designed to collect and analyze "real-world" clinical outcomes data for CABG Medical's Holly Graft(TM), a paclitaxel- eluting graft system in the treatment of patients with coronary artery disease Also, the Company announced today, that Dr. Peter Tesar of the Prince Charles Hospital in Brisbane, Australia will be presenting an overview of the Company's DEG clinical trial program at the Annual Scientific Meeting of the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) on June 4, in New York. The meeting is by invitation only and will be held at the Marriott Marquis. About CABG Medical CABG Medical, Inc. is a medical technology company developing technologies and therapies to improve the treatment of coronary heart disease by advancing conventional bypass surgery. We have designed our first product, the Holly Graft(TM) System, by leveraging our understanding of flow dynamics, material sciences and drug combinations to create a DEG system. Safe Harbor This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including regulatory actions, competition, and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission. http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO http://photoarchive.ap.org/ DATASOURCE: CABG Medical, Inc. CONTACT: Manny Villafana, Chairman & CEO, or John L. Babitt, President & COO, both of CABG Medical, Inc., +1-763-258-8005, Fax: +1-763-258-8008 Web site: http://www.cabgmedical.com/

Copyright